The Union Ministry of Health and Family Welfare has launched the ‘World Health Organization (WHO) India Country Cooperation Strategy 2019-2023: A Time of Transition programme in New Delhi.<br /><br /> ...

CHANDIGARH: To further ramp up the state’s testing facility and medical preparedness in the Covid battle, the Council of Ministers headed by Capt Amarinder Singh today cleared various appointments, on ...

The new study, published in the peer‑reviewed journal Drug Safety on December 11, suggested that shingles might occur after a Covid booster because important immune cells, called lymphocytes, can be ...

Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable therapies. The heavily back-loaded deal will see Moderna hand over just $3 ...

Moderna is pruning three investigational vaccines from its pipeline, while also securing additional funding, giving the company more financial flexibility as it strives to hit 10% revenue growth in ...

Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases. The ...

Shares of Moderna, Inc. (NASDAQ: MRNA) are falling Thursday. The Massachusetts-based biotech company made two significant announcements regarding its finances and business strategy. What To Know: ...

Moderna Inc. said it had secured a loan for up to $1.5 billion, a move aimed at shoring up the company’s finances as it struggles with the decline of its COVID business. The five-year loan facility ...

Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The story of the biotech company Moderna almost reads like a ...

Mast interviewed more than two dozen former and current Moderna employees, along with analysts, rival executives, investors, and experts in mRNA and vaccines to understand how the company arrived at ...

Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company’s investigational cytomegalovirus (CMV) vaccine. CMV is a ...